Dementia medical therapy: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| Line 21: | Line 21: | ||
Excessive NMDA stimulation can be induced by ischemia and lead to excitotoxicity, suggesting that agents that block pathologic stimulation of NMDA receptors may protect against further damage in patients with vascular dementia. | Excessive NMDA stimulation can be induced by ischemia and lead to excitotoxicity, suggesting that agents that block pathologic stimulation of NMDA receptors may protect against further damage in patients with vascular dementia. | ||
They have modest benefits in patients with moderate to severe AD | They have modest benefits in patients with moderate to severe AD<ref name="pmid12672860">{{cite journal |vauthors=Reisberg B, Doody R, Stöffler A, Schmitt F, Ferris S, Möbius HJ |title=Memantine in moderate-to-severe Alzheimer's disease |journal=N Engl J Med |volume=348 |issue=14 |pages=1333–41 |date=April 2003 |pmid=12672860 |doi=10.1056/NEJMoa013128 |url=}}</ref> | ||
==References== | ==References== | ||
Revision as of 00:40, 7 October 2020
|
Dementia Microchapters |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Medical Therapy
The mainstay of management of dementia is :
- Symptomatic
- Treatment of behavioral disturbances
- Environmental manipulations to support function
- Counseling with respect to safety issues.
More precise diagnosis is required for effective management and accurate prognosis. Medical therapy for dementia include:
They increase cholinergic transmission by inhibiting cholinesterase at the synaptic cleft and provide modest symptomatic benefit in some patients with dementia.
Excessive NMDA stimulation can be induced by ischemia and lead to excitotoxicity, suggesting that agents that block pathologic stimulation of NMDA receptors may protect against further damage in patients with vascular dementia.
They have modest benefits in patients with moderate to severe AD[1]
References
- ↑ Reisberg B, Doody R, Stöffler A, Schmitt F, Ferris S, Möbius HJ (April 2003). "Memantine in moderate-to-severe Alzheimer's disease". N Engl J Med. 348 (14): 1333–41. doi:10.1056/NEJMoa013128. PMID 12672860.